Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + chemotherapy
- Development stage
- Phase 2
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Fruquintinib is a potent and highly selective oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, which are critical mediators of tumor angiogenesis. In the context of clinical research led by Fudan University, specifically the FRU-RAS trial, fruquintinib is administered in combination with standard second-line chemotherapy regimens, such as mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluorouracil) or FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil). This combination therapy is designed to treat patients with RAS-mutant metastatic colorectal cancer (mCRC) by providing a dual mechanism of anti-angiogenic and cytotoxic activity. The regimen aims to offer a more effective therapeutic alternative to the current standard of care, bevacizumab plus chemotherapy, by leveraging fruquintinib's high selectivity and potency against VEGFR targets.
- Other names
- fruquintinib plus chemotherapyfruquintinib + mFOLFOX6fruquintinib + FOLFIRI
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNATOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on fruquintinib + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + chemotherapy.